4640 Results

People

  1. Saltz
    Saltz
  2. O'Reilly
    O'Reilly
  3. Abou-Alfa
    Abou-Alfa
  4. Kelsen
    Kelsen
  5. Ilson
    Ilson
  6. Kemeny
    Kemeny
  7. Janjigian
    Janjigian
  8. Reidy
    Reidy
  9. Jarnagin
    Jarnagin
  10. D'Angelica
    D'Angelica

Groups

  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)
  7. Epidemiology and Biostatistics (828)
  8. GSK Faculty (793)
  9. Department of Pathology and Laboratory Medicine (723)
  10. Biostatistics Service (661)
  1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention
    Journal Article

    Lowery, M. A.; Ptashkin, R.; Jordan, E.; Berger, M. F.; Zehir, A.; Capanu, M.; Kemeny, N. E.; O'Reilly, E. M.; El-Dika, I.; Jarnagin, W. R.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Adipocyte-derived lipids mediate melanoma progression via FATP proteins
    Journal Article

    Zhang, M.; Di Martino, J. S.; Bowman, R. L.; Campbell, N. R.; Baksh, S. C.; Simon-Vermot, T.; Kim, I. S.; Haldeman, P.; Mondal, C.; Yong-Gonzales, V.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)
    Meeting Abstract

    Tabernero, J.; Shitara, K.; Dvorkin, M.; Mansoor, W.; Arkenau, H. T.; Prokharau, A.; Alsina, M.; Ghidini, M.; Faustino, C.; Gorbunova, V.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy and safety results from IMblaze370, a randomised phase III study comparing atezolizumab + cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer
    Meeting Abstract

    Bendell, J.; Ciardiello, F.; Tabernero, J.; Tebbutt, N.; Eng, C.; Di Bartolomeo, M.; Falcone, A.; Fakih, M.; Kozloff, M.; Segal, N.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Merle, P.; Rimassa, L.; Ryoo, B.; Cicin, I.; Harris, W.; Banu, E.; Sarker, D.; Tan, B.; Van Vlierberghe, H.; Sen, S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib plus MEK inhibitor binimetinib plus anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer
    Meeting Abstract

    Van Cutsem, E.; Cuyle, P.; Huijberts, S.; Schellens, J.; Elez, E.; Yaeger, R.; Fakih, M.; Montagut, C.; Peeters, M.; Desai, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Treatment and testing patterns among patients with HER2+ advanced/metastatic gastric, esophageal or gastroesophageal junction (GEJ) adenocarcinoma in the United States
    Meeting Abstract

    Janjigian, Y.; Hess, L.; Zhu, Y.; Fang, Y.; Liepa, A.; Kuder, C.; Chin, S.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability-high (MSI-H) colorectal cancer: KEYNOTE-164
    Meeting Abstract

    Le, D.; Kavan, P.; Kim, T.; Burge, M.; Van Cutsem, E.; Hara, H.; Boland, P.; Van Laethem, J.; Geva, R.; Taniguchi, H.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A phase 3 study of chemotherapy + pembrolizumab vs chemotherapy + placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585 - Trial in progress
    Meeting Abstract

    Bang, Y.; Van Cutsem, E.; Fuchs, C.; Ohtsu, A.; Tabernero, J.; Ilson, D.; Hyung, W.; Strong, V.; Goetze, T.; Yoshikawa, T.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress
    Meeting Abstract

    Cheng, A.; Abou-Alfa, G.; Ren, Z.; Assenat, E.; Cubillo, A.; Pluntke, S.; Rimassa, L.; Ross, P.; Wyrwicz, L.; Hou, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save